Sapphiros and Cencora, formerly AmerisourceBergen Corporation, Enter into Distribution Agreement

Rhea-AI Summary

Sapphiros (COR) partners with Cencora, Inc. to distribute COVID-19 Antigen Rapid Tests and future diagnostic technologies, aiming to enhance accessibility and convenience for consumers nationwide. The agreement also includes access to upcoming Sapphiros technologies, such as multiplexed molecular diagnostics platform, rapid lateral flow tests for diseases beyond COVID-19, and the Satio™ blood collection patch in early 2024.

BOSTON, Nov. 22, 2023 /PRNewswire/ -- Sapphiros, a platform company dedicated to building the next generation of consumer diagnostic technologies, is proud to announce it has entered into a distribution agreement with Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation.

Under the agreement, Cencora will distribute the Sapphiros GoToKnow™ COVID-19 Antigen Rapid Tests to pharmacies across the United States. This strategic partnership promises to enhance accessibility and convenience for those seeking reliable COVID-19 testing solutions nationwide. 

In the future, Cencora will also have access to the future Sapphiros technologies including a fully disposable, low-cost multiplexed molecular diagnostics platform, additional rapid lateral flow tests for diseases beyond COVID-19 and the Satio™ novel blood collection patch coming in early 2024. 

"This is a significant milestone for our company and further validates Sapphiros's unique and transformational technologies," said Mark Gladwell, CEO of Sapphiros. "We are honored to partner with Cencora to bring this product as well as future innovative product offerings directly to patients across the United States enabling the consumer to directly access their diagnostic results and manage their health."

About Sapphiros

Sapphiros, backed by KKR and Neoenta, is a privately held consumer diagnostics platform company. Sapphiros's portfolio of capabilities and technologies includes novel sample collection, next generation diagnostics, computational biology, and printed electronics, which help consumers access important diagnostic results globally. Knowing Now Moves Us™

About Cencora
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $250 billion in annual revenue. Learn more at www.investor.cencora.com

For further information: Sapphiros, press@sapphiros.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sapphiros-and-cencora-formerly-amerisourcebergen-corporation-enter-into-distribution-agreement-301995452.html

SOURCE Sapphiros

FAQ

What is the name of the company mentioned in the press release and its ticker symbol?

The company mentioned is Sapphiros and its ticker symbol is COR.

What is the distribution agreement about and who is the partner company?

The distribution agreement is for the distribution of Sapphiros GoToKnow™ COVID-19 Antigen Rapid Tests to pharmacies across the United States. The partner company is Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation.

What future technologies are included in the agreement?

The future technologies included in the agreement are a fully disposable, low-cost multiplexed molecular diagnostics platform, additional rapid lateral flow tests for diseases beyond COVID-19, and the Satio™ novel blood collection patch coming in early 2024.

Who is the CEO of Sapphiros and what does he say about the partnership?

The CEO of Sapphiros is Mark Gladwell, and he mentioned that the partnership with Cencora is a significant milestone for the company and further validates Sapphiros's unique and transformational technologies.